Free Trial
Want deep insights into your competitors & competitive landscape? Try Patsnap Eureka!

Top 20 Key Players companies in Nicotinamide mononucleotide
by Highest Patent Value in the China in 2018

The Nicotinamide mononucleotide top 20 is Discovery PatSnap’ annual ranking of the top 20 Highest Patent Value Nicotinamide mononucleotide Key Players in the China. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2018, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
Nicotinamide mononucleotide ("NMN", "NAMN", and "β-NMN") is a nucleotide derived from ribose and nicotinamide. Like nicotinamide riboside, NMN is a derivative of niacin, and humans have enzymes that can use NMN to generate nicotinamide adenine dinucleotide (NADH).
#
Company Name
Region
Tech Topics
Total
1
Avg patent value: 92,000
2
Medicine,Bead,Cardiovascular agent,
...[+2]
Avg patent value: 15,000
3
Avg patent value: 3,600
4
Avg patent value: 3,500
5
Avg patent value: 3,500
6
Avg patent value: 3,500
7
Avg patent value: 3,480
8
Nutrition,Health care,Arachidonic acid,
...[+2]
Avg patent value: 3,466
9
Avg patent value: 3,466
10
Avg patent value: 3,400
11
Health care,Research system,International health,
...[+2]
Avg patent value: 3,400
12
Avg patent value: 3,400
13
Avg patent value: 3,400
14
Plasma Volume Expander,Antibiotics,Drug,
...[+1]
Avg patent value: 3,400
15
Zhongke Health Industry Group Corp., Ltd
Avg patent value: 3,400
16
Avg patent value: 3,400
17
Health care,Genetic engineering,Enzyme,
...[+2]
Avg patent value: 3,300
18
Avg patent value: 3,300
19
Avg patent value: 3,300
20
Avg patent value: 3,300
Page generation time: Jun 19 2025